Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: A retrospective study from the United States database

Keyphrases

• United States 100%
• Adult Patients 100%
• Immune Checkpoint Inhibitors 100%
• Melanoma 100%
• Metastasizing 100%
• State Database 100%
• Metastatic Melanoma 25%
• Patient Survival 25%
• Pre-immune 25%
• Low Risk 16%
• Surveillance Epidemiology 16%
• Non-Hispanic White 16%
• Ipilimumab 16%
• End Results Database 16%
• High Risk 8%
• Male Gender 8%
• No Significant Difference 8%
• Overall Survival 8%
• Median Overall Survival 8%
• Chemotherapy 8%
• Extracted Data 8%
• Radiotherapy 8%
• Cox Proportional Hazard Analysis 8%
• Population Level 8%
• Delayed Diagnosis 8%
• Potential Change 8%
• Combination Therapy 8%
• Log-rank Test 8%
• United States Food 8%
• Nivolumab 8%
• Married Men 8%

Medicine and Dentistry

• Retrospective Study 100%
• Immune Checkpoint Inhibitor 100%
• Melanoma 100%
• Metastatic Melanoma 25%
• Overall Survival 16%
• Surveillance, Epidemiology, and End Results 16%
• Ipilimumab 16%
• Combination Therapy 8%
• Proportional Hazards Model 8%
• Log Rank Test 8%
• Nivolumab 8%
• Radiation Therapy 8%